The purpose of this study is to evaluate the topical safety (tolerability/acceptability) and efficacy of two facial sunscreen in improving wrinkles, fine lines and melasma after 84 +/- 2 days of use under normal conditions on the face by adult participants. For these investigational products, safety parameters, clinical efficacy, instrumental efficacy (assessment of color intensity and size of melasma spots and assessment of wrinkles and fine lines), facial imaging, and self-perceived efficacy through subjective questionnaire and quality of life questionnaires (MELASQol) will be evaluated, as well as an open emotional statement written by the participant at the end of use experience".
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events
Timeframe: Up to 84 +/- 2 days
Improvement in Assessment of Melasma Color Intensity Using Chroma Meter CR 400 at Day 28
Timeframe: Baseline and Day 28
Improvement in Assessment of Melasma Color Intensity Using Chroma Meter CR 400 at Day 56
Timeframe: Baseline and Day 56
Improvement in Assessment of Melasma Color Intensity Using Chroma Meter CR 400 at Day 84 +/- 2
Timeframe: Baseline and Day 84 +/- 2
Number of Participants with Improvement From Baseline in Melasma, and Wrinkles and Fine lines Assessed Using the Visia-CR Facial Imaging Booth at Day 28
Timeframe: Baseline and Day 28
Number of Participants with Improvement From Baseline in Melasma, and Wrinkles and Fine lines Assessed Using the Visia-CR Facial Imaging Booth at Day 56
Timeframe: Baseline and Day 56
Number of Participants with Improvement From Baseline in Melasma, and Wrinkles and Fine lines Assessed Using the Visia-CR Facial Imaging Booth at Day 84 +/- 2
Timeframe: Baseline and Day 84 +/- 2
Number of Participants With Improvement From Baseline in Quality of Life as Assessed by the Melasma Quality of Life Scale (MELASQOL) at Day 28
Timeframe: Day 28
Number of Participants With Improvement From Baseline in Quality of Life as Assessed by the Melasma Quality of Life Scale (MELASQOL) at Day 56
Timeframe: Day 56
Number of Participants With Improvement From Baseline in Quality of Life as Assessed by the Melasma Quality of Life Scale (MELASQOL) at Day 84 +/- 2
Timeframe: Day 84 +/- 2
Participant's Self-perceived Questionnaire to Assess their Perception of the Color/Tone of Sunscreen
Timeframe: Baseline (Day 1)
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 28
Timeframe: Day 28
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 84 +/- 2
Timeframe: Day 84 +/- 2
Testimonial Regarding the Experience with Sunscreen
Timeframe: End of the Study (84 +/- 2 days)
Topical Tolerability as Assessed by the Dermatologist
Timeframe: Up to 84 +/- 2 days
Number of Participants with Improvement From Baseline in Melasma by mMASI Scale as Assessed by the Dermatologist
Timeframe: Up to 84 +/- 2 days
Clinical Efficacy Evaluations as Assessed by the Dermatologist on Day 28
Timeframe: Day 28
Clinical Efficacy Evaluations as Assessed by the Dermatologist on Day 56
Timeframe: Day 56
Clinical Efficacy Evaluations as Assessed by the Dermatologist on Day 84 +/- 2
Timeframe: Day 84 +/- 2